

Minesh Mehta

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4699731/publications.pdf](https://exaly.com/author-pdf/4699731/publications.pdf)

Version: 2024-02-01

550
papers

52,697
citations

1269

109
h-index

1829

209
g-index

759
all docs

759
docs citations

759
times ranked

35670
citing authors

#	ARTICLE	IF	CITATIONS
1	Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer. <i>Medical Dosimetry</i> , 2024, 49, 121-126.	0.8	0
2	Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors. <i>Tomography</i> , 2024, 10, 169-180.	1.9	0
3	ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. <i>Journal of Clinical Oncology</i> , 2024, 42, 1542-1552.	15.4	11
4	Clinical application of an institutional fractionated stereotactic radiosurgery (FSRS) program for brain metastases delivered with MRIdian [®] BrainTx [™] . <i>Medical Dosimetry</i> , 2024, , .	0.8	0
5	Proton Therapy: Current Status and Controversies. <i>JCO Oncology Practice</i> , 2024, 20, 747-749.	2.8	0
6	Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. <i>Journal of Clinical Oncology</i> , 2024, 42, 2588-2598.	15.4	0
7	Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities. <i>Brachytherapy</i> , 2024, , .	0.8	0
8	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.2	56
9	NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 1285-1295.	15.4	69
10	Treatment of glioblastoma using MRIdian [®] A3i BrainTx [™] : Imaging and treatment workflow demonstration. <i>Medical Dosimetry</i> , 2023, 48, 127-133.	0.8	6
11	Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. <i>Cancer Discovery</i> , 2023, 13, 2370-2393.	14.2	39
12	Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience. <i>Brachytherapy</i> , 2023, 22, 872-881.	0.8	3
13	RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. <i>Journal of Clinical Oncology</i> , 2023, 41, 5187-5199.	15.4	47
14	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.2	20
15	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.2	84
16	Systematic evaluation and plan quality assessment of the Leksell [®] gamma knife [®] lightning dose optimizer. <i>Medical Dosimetry</i> , 2022, 47, 70-78.	0.8	12
17	Dose-Escalated Magnetic Resonance Image-Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating. <i>Advances in Radiation Oncology</i> , 2022, 7, 100840.	1.2	10
18	CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 166, 101-109.	0.6	21

#	ARTICLE	IF	CITATIONS
19	Relationship between insurance status and interhospital transfers among cancer patients in the United States. <i>BMC Cancer</i> , 2022, 22, 121.	2.6	3
20	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 60-74.	0.8	46
21	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. <i>Scientific Reports</i> , 2022, 12, 4567.	3.4	11
22	Hospitalization rates from radiotherapy complications in the United States. <i>Scientific Reports</i> , 2022, 12, 4371.	3.4	6
23	Evaluation of a prospective radiation oncology departmental team review process using standardized simulation directives. <i>Radiotherapy and Oncology</i> , 2022, 170, 102-110.	0.6	1
24	Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. <i>Cancers</i> , 2022, 14, 2020.	3.8	9
25	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	2.8	14
26	Intracranial Tumors. , 2022, , 177-199.		0
27	RONC-13. Change in hippocampus volume as a function of radiation dose: Results from a prospective trial with standardized imaging and morphometric evaluation. <i>Neuro-Oncology</i> , 2022, 24, i179-i179.	1.2	1
28	Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse. <i>Radiotherapy and Oncology</i> , 2022, 173, 84-92.	0.6	7
29	Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. <i>Cancers</i> , 2022, 14, 2946.	3.8	5
30	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	15.4	36
31	Zero Setup Margin Mask versus Frame Immobilization during Gamma Knife® Iconâ„¢ Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2022, 14, 3392.	3.8	9
32	Access to Radiation Therapy: From Local to Global and Equality to Equity. <i>JCO Global Oncology</i> , 2022, , .	2.3	15
33	Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 47-53.	1.5	6
34	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021, 23, 1125-1138.	1.2	17
35	Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab010.	0.7	17
36	Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage nonâ€“small-cell lung cancer. <i>Medical Dosimetry</i> , 2021, 46, 247-252.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	1.2	84
38	Novel Radiation Approaches. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 211-223.	1.8	8
39	Die Rosenberg und der Kriegsverbrecher: Der Fall Max Merten. , 2021, , 123-154.		0
40	Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. <i>Current Oncology</i> , 2021, 28, 1537-1543.	2.3	5
41	Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes. <i>Advances in Radiation Oncology</i> , 2021, 6, 100651.	1.2	3
42	Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. <i>Cancers</i> , 2021, 13, 2186.	3.8	6
43	Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report. <i>Medical Dosimetry</i> , 2021, 46, 384-388.	0.8	7
44	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. <i>Radiotherapy and Oncology</i> , 2021, 159, 17-20.	0.6	7
45	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2021, 13, 3682.	3.8	19
46	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		46
47	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. <i>Neuro-Oncology Practice</i> , 2021, 8, 674-683.	1.5	3
48	Effect of Postoperative Radiation Therapy Timing on Survival in Pediatric and Young Adult Ependymoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100691.	1.2	1
49	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , 2021, 8, 662-673.	1.5	6
50	Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. <i>JCO Precision Oncology</i> , 2021, 5, 1397-1407.	3.2	6
51	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, iii20-iii20.	0.7	0
52	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, iii15-iii16.	0.7	0
53	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 155, 297-306.	3.0	8
54	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. <i>Discover Oncology</i> , 2021, 12, 48.	2.2	7

#	ARTICLE	IF	CITATIONS
55	A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation. <i>Practical Radiation Oncology</i> , 2021, 11, e366-e375.	2.1	1
56	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Journal of Neuro-Oncology</i> , 2021, 155, 363-372.	3.0	11
57	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab166.	0.7	5
58	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. <i>Scientific Reports</i> , 2021, 11, 22152.	3.4	4
59	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	2.9	9
60	High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 790-799.	0.8	129
61	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa124.	0.7	6
62	Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 964.	1.7	4
63	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3407-3417.	15.4	126
64	Radiotherapy innovations to optimize brain metastases control. <i>Neuro-Oncology</i> , 2020, 22, 1715-1717.	1.2	0
65	Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 806-812.	1.3	2
66	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. <i>Journal of Clinical Oncology</i> , 2020, 38, 3773-3784.	15.4	264
67	Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1753-1762.	0.5	15
68	A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1529-1535.	2.3	3
69	Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes. <i>Neuro-Oncology</i> , 2020, 22, 1062-1064.	1.2	2
70	NRG/RTOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	4.1	31
71	Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. <i>Frontiers in Oncology</i> , 2020, 10, 254.	2.9	24
72	Early imaging marker of progressing glioblastoma: a window of opportunity. <i>Journal of Neuro-Oncology</i> , 2020, 148, 629-640.	3.0	3

#	ARTICLE	IF	CITATIONS
73	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. <i>Neuro-Oncology</i> , 2020, 22, 1359-1367.	1.2	53
74	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	0.8	90
75	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. <i>Neuro-Oncology</i> , 2020, 22, 94-102.	1.2	61
76	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. <i>Journal of Clinical Oncology</i> , 2020, 38, 1019-1029.	15.4	535
77	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 720-725.	0.8	35
78	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	652
79	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. <i>Acta Neuropathologica</i> , 2020, 139, 1071-1088.	7.9	57
80	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	25
81	Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. <i>Radiation Research</i> , 2020, 194, 1.	1.5	16
82	Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review. <i>Neurosurgery</i> , 2019, 84, 19-29.	1.3	52
83	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. <i>Advances in Radiation Oncology</i> , 2019, 4, 579-586.	1.2	18
84	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 39-45.	1.8	26
85	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 205-210.	3.0	31
86	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019, 21, 1100-1117.	1.2	41
87	The association between BMI and BSA and temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. <i>Neuro-Oncology Practice</i> , 2019, 6, 473-478.	1.5	5
88	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	3.0	139
89	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	1.3	21
90	Basic principles of brain tumor radiotherapy. , 2019, , 245-262.		1

#	ARTICLE	IF	CITATIONS
91	The Complexity of Managing Large Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2019, 104, 483-484.	0.8	6
92	WHO II and III Gliomas. , 2019, , 217-236.		1
93	Updates in the management of intradural spinal cord tumors: a radiation oncology focus. Neuro-Oncology, 2019, 21, 707-718.	1.2	22
94	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918.	1.1	8
95	NRG brain tumor specialists consensus guidelines for glioblastoma contouring. Journal of Neuro-Oncology, 2019, 143, 157-166.	3.0	63
96	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	5.2	13
97	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	2.7	25
98	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. International Journal of Radiation Oncology Biology Physics, 2019, 103, 878-886.	0.8	10
99	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. Neuro-Oncology, 2019, 21, vi137-vi137.	1.2	21
100	ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi20-vi20.	1.2	12
101	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology, 2019, 21, 167-178.	1.2	188
102	Low-Grade Glioma Radiotherapy Treatment and Trials. Neurosurgery Clinics of North America, 2019, 30, 111-118.	1.8	67
103	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery, 2019, 84, 66-76.	1.3	8
104	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro-Oncology, 2018, 20, 966-974.	1.2	34
105	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro-Oncology, 2018, 20, 666-673.	1.2	115
106	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. Strahlentherapie Und Onkologie, 2018, 194, 365-374.	2.2	17
107	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	10.8	46
108	Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis. Neuro-Oncology, 2018, 20, 2-3.	1.2	7

#	ARTICLE	IF	CITATIONS
109	Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 59-60.	0.8	3
110	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 13-18.	4.5	53
111	Preradiation Chemotherapy for Adult High-risk Medulloblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 588-594.	1.3	18
112	Brain Metastases in Lung Cancer With Targetable Mutations—Reply. <i>JAMA Oncology</i> , 2018, 4, 422.	7.3	0
113	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018, 136, 79-86.	3.0	27
114	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 38-44.	0.8	55
115	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 191-196.	1.3	51
116	Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 687-693.	1.4	27
117	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	1.2	3
118	Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3277-3281.	15.4	0
119	What is the evidence for the clinical value of SBRT in cancer of the cervix?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 574-579.	0.7	15
120	Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide. <i>JAMA Oncology</i> , 2018, 4, 1405.	7.3	149
121	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 845-853.	0.8	24
122	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. <i>Neuro-Oncology</i> , 2018, 20, 1652-1660.	1.2	49
123	Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 221-230.	2.5	18
124	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. <i>Lancet Oncology</i> , The, 2018, 19, e366.	10.8	10
125	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 341-349.	3.0	14
126	Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. <i>Journal of Neuro-Oncology</i> , 2018, 140, 421-426.	3.0	22

#	ARTICLE	IF	CITATIONS
127	Recent advances in managing brain metastasis. F1000Research, 2018, 7, 1772.	1.6	70
128	Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. Oncotarget, 2018, 9, 6883-6896.	2.1	38
129	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-Oncology, 2017, 19, now236.	1.2	41
130	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology, 2017, 19, now208.	1.2	111
131	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. JAMA Oncology, 2017, 3, 784.	7.3	84
132	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 411-415.	0.6	20
133	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 820-828.	0.8	31
134	The role of radiation in treating glioblastoma: here to stay. Journal of Neuro-Oncology, 2017, 134, 479-485.	3.0	30
135	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.8	60
136	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stageAI disease. Strahlentherapie Und Onkologie, 2017, 193, 515-524.	2.2	13
137	Lung Cancer. , 2017, , 349-384.		0
138	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiotherapy and Oncology, 2017, 123, 376-381.	0.6	89
139	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	148
140	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of Neuro-Oncology, 2017, 133, 589-594.	3.0	25
141	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	1.2	113
142	P2.06-034 METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC. Journal of Thoracic Oncology, 2017, 12, S1092-S1093.	1.2	0
143	Medulloblastoma in Adults. , 2017, , 917-938.		0
144	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology, 2017, 35, 361-369.	15.4	115

#	ARTICLE	IF	CITATIONS
145	The Changing Role of Whole-Brain Radiotherapy. <i>JAMA Oncology</i> , 2017, 3, 1021.	7.3	19
146	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 812-816.	0.8	167
147	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	3.0	22
148	Radiation Therapy in the Treatment of Low Grade Gliomas. , 2017, , 579-594.		0
149	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 193-199.	3.0	60
150	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 362-371.	0.8	82
151	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 228-235.	0.8	64
152	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. <i>Journal of Neuro-Oncology</i> , 2017, 131, 105-115.	3.0	66
153	Estimating Survival in Patients With Lung Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 827.	7.3	568
154	State of the art: the evolving role of RT in combined modality therapy for GBM. <i>Journal of Neuro-Oncology</i> , 2017, 134, 477-478.	3.0	0
155	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017, 8, 35523-35531.	2.1	9
156	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2016, 34, 4057-4057.	15.4	0
157	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 75-81.	4.1	17
158	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 644-664.	1.4	58
159	Clinical ramifications of "genomic staging" of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 129, 195-199.	3.0	12
160	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	1.2	220
161	A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. <i>Cancer</i> , 2016, 122, 1483-1501.	4.1	168
162	Stereotactic Radiosurgery for Treatment of Brain Metastases. <i>Journal of Oncology Practice</i> , 2016, 12, 703-712.	3.0	45

#	ARTICLE	IF	CITATIONS
163	Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. <i>Cell Cycle</i> , 2016, 15, 2265-2274.	2.8	67
164	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. <i>Journal of Clinical Oncology</i> , 2016, 34, 1620-1625.	15.4	123
165	Proton therapy for paediatric CNS tumours – improving treatment-related outcomes. <i>Nature Reviews Neurology</i> , 2016, 12, 334-345.	10.0	54
166	Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 145-154.	2.6	58
167	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. <i>New England Journal of Medicine</i> , 2016, 374, 1344-1355.	30.1	853
168	Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 207-216.	3.0	32
169	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 406-413.	0.8	86
170	Proton radiotherapy for gynecologic neoplasms. <i>Acta Oncologica</i> , 2016, 55, 1257-1265.	1.9	23
171	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. <i>Archives of Virology</i> , 2016, 161, 3161-3169.	1.9	23
172	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3107-3108.	15.4	2
173	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
174	Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma – An Easy Question Turned Difficult: Treat the Scan or the Patient?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1281-1282.	15.4	6
175	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	15.4	168
176	Glioblastoma: Radiation treatment margins, how small is large enough?. <i>Practical Radiation Oncology</i> , 2016, 6, 298-305.	2.1	39
177	International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1102-1106.	0.8	9
178	What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?. <i>Journal of Neuro-Oncology</i> , 2016, 127, 303-311.	3.0	15
179	Pathologic deposition of non-amyloid immunoglobulin in the brain leading to mass effect and neurologic deficits. <i>Journal of Clinical Neuroscience</i> , 2016, 30, 143-145.	1.6	3
180	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. <i>Journal of Neuro-Oncology</i> , 2016, 126, 327-336.	3.0	35

#	ARTICLE	IF	CITATIONS
181	A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. <i>Journal of Neuro-Oncology</i> , 2016, 126, 309-316.	3.0	59
182	Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. <i>Neuro-Oncology</i> , 2016, 18, 565-574.	1.2	98
183	Anteriorly Oriented Beam Arrangements with Daily in Vivo Range Verification for Proton Therapy of Prostate Cancer: Rectal Toxicity Rates. <i>International Journal of Particle Therapy</i> , 2016, 2, 509-517.	1.9	7
184	Free Breathing versus Breath-Hold Scanning Beam Proton Therapy and Cardiac Sparing in Breast Cancer. <i>International Journal of Particle Therapy</i> , 2016, 3, 407-413.	1.9	13
185	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 75-81.	4.1	4
186	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. <i>International Journal of Particle Therapy</i> , 2016, 2, 555-569.	1.9	0
187	An overview of modern proton therapy. <i>Chinese Clinical Oncology</i> , 2016, 5, 48-48.	1.3	4
188	RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE. <i>Neuro-Oncology</i> , 2015, 17, v196.1-v196.	1.2	2
189	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. <i>Neuro-Oncology</i> , 2015, 17, v6.2-v6.	1.2	2
190	NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933. <i>Neuro-Oncology</i> , 2015, 17, v149.1-v149.	1.2	0
191	Proton Beam Therapy Basics. <i>Journal of the American College of Radiology</i> , 2015, 12, 1204-1206.	1.8	1
192	BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868). <i>Neuro-Oncology</i> , 2015, 17, v49.2-v49.	1.2	0
193	RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825. <i>Neuro-Oncology</i> , 2015, 17, v195.3-v195.	1.2	0
194	OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY. <i>Neuro-Oncology</i> , 2015, 17, viii16.2-viii16.	1.2	0
195	ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRIStINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2015, 17, v3.1-v3.	1.2	4
196	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e99-e104.	4.1	14
197	Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. <i>Clinical Lung Cancer</i> , 2015, 16, 413-430.	2.7	46
198	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , 2015, 16, e270-e278.	10.8	771

#	ARTICLE	IF	CITATIONS
199	ATNT-10 DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v12.2-v12.	1.2	1
200	ATCT-29 INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525. <i>Neuro-Oncology</i> , 2015, 17, v8.1-v8.	1.2	0
201	ATCT-08 THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG. <i>Neuro-Oncology</i> , 2015, 17, v2.4-v2.	1.2	3
202	ATCT-27 NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v7.3-v7.	1.2	3
203	Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. <i>Neuro-Oncology</i> , 2015, 17, 999-1006.	1.2	17
204	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. <i>Neuro-Oncology Practice</i> , 2015, 2, 57-61.	1.5	1
205	ATCT-12 RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA). <i>Neuro-Oncology</i> , 2015, 17, v3.4-v3.	1.2	1
206	RTRB-14 TREATMENT RECOMMENDATIONS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA LACK WORLDWIDE CONSENSUS. <i>Neuro-Oncology</i> , 2015, 17, v198.2-v198.	1.2	0
207	Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 497-504.	0.8	136
208	Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review. <i>Clinical Breast Cancer</i> , 2015, 15, e163-e166.	2.6	21
209	Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 564-570.	0.8	27
210	Whole-Brain Radiotherapy for Brain Metastases: Is the Therapeutic Window Enlarging?. , 2015, , 41-56.		0
211	In Regard to Badiyan et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 453-454.	0.8	3
212	Should we irradiate a brain tumor in a patient with parkinsonism? A case report and literature review. <i>Practical Radiation Oncology</i> , 2015, 5, e327-e335.	2.1	2
213	Atypical meningioma: Randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 59.	0.9	46
214	The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. <i>Neuro-Oncology</i> , 2015, 17, 919-923.	1.2	23
215	Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 409-417.	3.0	89
216	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015, 17, 992-998.	1.2	120

#	ARTICLE	IF	CITATIONS
217	Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 776-783.	1.6	59
218	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. <i>Journal of Neuro-Oncology</i> , 2015, 124, 413-420.	3.0	27
219	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2015, 33, 1986-1986.	15.4	0
220	Management of solitary and multiple brain metastases from breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 87-93.	0.2	19
221	Stereotactic Radiosurgery for Glioblastoma. <i>Cureus</i> , 2015, 7, e413.	0.5	32
222	Radiation-induced brain damage, impact of Michael Robbins's™ work and the need for predictive biomarkers. <i>International Journal of Radiation Biology</i> , 2014, 90, 742-752.	1.5	17
223	Prophylactic Cranial Irradiation: Recent Outcomes and Innovations. <i>CNS Oncology</i> , 2014, 3, 219-230.	2.7	14
224	Recent Updates in the Treatment of Glioblastoma: Introduction. <i>Seminars in Oncology</i> , 2014, 41, S1-S3.	2.3	6
225	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014, 16, 567-578.	1.2	143
226	Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 2048-2049.	30.1	98
227	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3810-3816.	15.4	928
228	Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 480-485.	1.3	16
229	Reirradiation for Locoregionally Recurrent Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 70-76.	1.3	37
230	It Is Time to Reevaluate the Management of Patients With Brain Metastases. <i>Neurosurgery</i> , 2014, 75, 1-9.	1.3	24
231	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2014, 116, 187-193.	3.0	63
232	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	30.1	2,351
233	Potential of glyburide to reduce intracerebral edema in brain metastases. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 379-388.	2.8	8
234	Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02. <i>Journal of Clinical Oncology</i> , 2014, 32, 535-541.	15.4	99

#	ARTICLE	IF	CITATIONS
235	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 1634-1635.	15.4	2
236	Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 526-531.	0.8	158
237	Strategies to Prevent Brain Metastasis in High-Risk Non-Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation. <i>Clinical Lung Cancer</i> , 2014, 15, 433-440.	2.7	16
238	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH1</i> . <i>Journal of Clinical Oncology</i> , 2014, 32, 783-790.	15.4	363
239	High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients. <i>Digestive and Liver Disease</i> , 2014, 46, 760-761.	0.9	4
240	AT-13 * R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRIStINE (PCV) IN LOW-GRADE GLIOMA: RESULTS BY HISTOLOGIC TYPE. <i>Neuro-Oncology</i> , 2014, 16, v11-v11.	1.2	7
241	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. <i>Journal of Neuro-Oncology</i> , 2013, 112, 467-472.	3.0	141
242	RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1206-1211.	0.8	143
243	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. <i>Neuro-Oncology</i> , 2013, 15, 1429-1437.	1.2	776
244	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 880-884.	0.8	55
245	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. <i>Neuro-Oncology</i> , 2013, 15, 1568-1579.	1.2	91
246	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4085-4091.	15.4	866
247	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013, 31, 337-343.	15.4	998
248	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	10.8	116
249	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	10.8	121
250	Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4343-4348.	15.4	134
251	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). <i>Journal of Neuro-Oncology</i> , 2013, 111, 33-39.	3.0	15
252	In Regard to Sperduto et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 809-810.	0.8	9

#	ARTICLE	IF	CITATIONS
253	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 348-354.	0.8	315
254	A Roundtable Discussion on the Clinical Challenges and Options for the Treatment of Glioblastoma: Introducing a Novel Modality, TTFields. <i>Seminars in Oncology</i> , 2013, 40, S2-S4.	2.3	5
255	A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1312-1318.	0.8	257
256	Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). <i>Biomarker Research</i> , 2013, 1, 29.	7.0	4
257	Pseudoprogression after glioma therapy: a comprehensive review. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 389-403.	2.8	94
258	Molecular Profiling in Non-“Small Cell Lung Cancer: A Step Toward Personalized Medicine. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 481-491.	2.5	54
259	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 686-693.	6.4	40
260	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 310-315.	1.3	91
261	Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 222-230.	2.0	9
262	Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4076-4084.	15.4	114
263	Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report. <i>Tumori</i> , 2013, 99, e38-e42.	1.1	5
264	Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy. , 2013, 4, 59.		7
265	Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 655-667.	2.6	14
266	Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non-“Small-Cell Lung Cancer: The ECOG 3598 Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 616-622.	15.4	75
267	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012, 14, 1511-1518.	1.2	96
268	Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802. <i>Journal of Clinical Oncology</i> , 2012, 30, 3065-3070.	15.4	308
269	Reply to M.C. Chamberlain et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3316-3317.	15.4	2
270	Integrated phase II/III clinical trials in oncology: A case study. <i>Clinical Trials</i> , 2012, 9, 741-747.	1.8	7

#	ARTICLE	IF	CITATIONS
271	In regards to Kirby <i>et al</i> . "Physics strategies for sparing neural stem cells during whole-brain radiation treatments," [Med. Phys. 38, 5338 (2011)]. Medical Physics, 2012, 39, 1677-1678.	2.9	0
272	Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	14.2	311
273	A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-Oncology, 2012, 14, 910-918.	1.2	127
274	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2111-2117.	0.8	331
275	Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 83, e487-e493.	0.8	175
276	In Regard to Yamamoto <i>et al</i> . International Journal of Radiation Oncology Biology Physics, 2012, 84, 875-876.	0.8	3
277	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. Journal of Clinical Oncology, 2012, 30, 419-425.	15.4	1,238
278	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology, 2012, 30, 2648-2653.	15.4	173
279	Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases. Journal of Neuro-Oncology, 2012, 108, 141-146.	3.0	26
280	Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology, 2012, 106, 147-153.	3.0	117
281	Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica, 2012, 123, 205-222.	7.9	169
282	Stereotactic Irradiation. , 2012, , 331-343.		2
283	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta Oncologica, 2011, 50, 772-776.	1.9	26
284	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. Cancer Discovery, 2011, 1, 442-456.	14.2	357
285	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Medical Hypotheses, 2011, 76, 410-413.	1.5	15
286	In response to "The distribution of brain metastases in the perihippocampal region (Regarding Gondi <i>et al</i>)" Tj ETQq0,0 0 rgBJ /Overlock	0,6	3
287	Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and tomotherapy. Radiotherapy and Oncology, 2011, 100, 241-246.	0.6	150
288	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 623-630.	0.8	210

#	ARTICLE	IF	CITATIONS
289	A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1422-1427.	0.8	29
290	Reply to Drs. Mulvenna and Holt. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1194-1195.	0.8	0
291	Crimean-Congo haemorrhagic fever in India. <i>Lancet, The</i> , 2011, 378, 372.	12.1	58
292	Combined Modality Approaches in the Management of Adult Glioblastoma. <i>Frontiers in Oncology</i> , 2011, 1, 36.	2.9	8
293	Stereotactic Body Radiation Therapy in Non-“Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 432-441.	1.3	14
294	Temozolomide-induced severe myelosuppression. <i>Anti-Cancer Drugs</i> , 2011, 22, 104-110.	1.4	19
295	A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 388-394.	1.3	17
296	Current practices of driving restriction implementation for patients with brain tumors. <i>Journal of Neuro-Oncology</i> , 2011, 103, 641-647.	3.0	18
297	Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. <i>Journal of Neuro-Oncology</i> , 2011, 104, 351-356.	3.0	43
298	Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of 6 brain metastases: a multi-institutional phase II trial. <i>Journal of Neuro-Oncology</i> , 2011, 105, 301-308.	3.0	16
299	Presentation, patterns of care, and survival in patients with brain metastases. <i>Cancer</i> , 2011, 117, 2505-2512.	4.1	173
300	In Response to Dr. Knisely and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 958.	0.8	1
301	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 893-899.	0.8	32
302	Pro: Lung Cancer in 2011: A Time for Optimism and Investment in New Approaches and Technologies with a Commitment to Produce Evidence-Based Data. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1231-1234.	6.6	0
303	Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 319-327.	0.4	111
304	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2689-2695.	15.4	206
305	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 1118-1124.	1.2	102
306	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. <i>Clinical Cancer Research</i> , 2011, 17, 4872-4881.	7.2	60

#	ARTICLE	IF	CITATIONS
307	Advances in Radiation Oncology of Lung Cancer. Medical Radiology, 2011, , 725-733.	0.0	0
308	Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics, 2011, 11, 1399-1409.	2.8	15
309	The Dandelion Effect: Treat the Whole Lawn or Weed Selectively?. Journal of Clinical Oncology, 2011, 29, 121-124.	15.4	30
310	It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. Journal of Clinical Oncology, 2011, 29, 3211-3213.	15.4	22
311	Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology, 2011, 13, 353-361.	1.2	106
312	Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients. Frontiers in Bioscience - Elite, 2011, E3, 1182-1191.	1.8	2
313	Novel insights into the management of brain metastases. Current Opinion in Neurology, 2010, 23, 556-562.	3.7	18
314	Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. International Journal of Radiation Oncology Biology Physics, 2010, 77, 662-669.	0.8	48
315	The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 85-96.	3.0	127
316	The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 97-102.	3.0	128
317	The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 103-114.	3.0	291
318	The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. Journal of Neuro-Oncology, 2010, 96, 115-142.	3.0	49
319	The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 17-32.	3.0	280
320	The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 33-43.	3.0	369
321	The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 71-83.	3.0	142
322	The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2010, 96, 45-68.	3.0	457
323	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology, 2010, 96, 211-217.	3.0	167
324	Fractionated radiotherapy for intracranial meningiomas. Journal of Neuro-Oncology, 2010, 99, 349-356.	3.0	22

#	ARTICLE	IF	CITATIONS
325	Opportunities for clinical research in meningioma. <i>Journal of Neuro-Oncology</i> , 2010, 99, 417-422.	3.0	23
326	Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 188-193.	0.8	46
327	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 655-661.	0.8	889
328	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 326-332.	0.8	484
329	Hippocampal-Sparing Whole-Brain Radiotherapy: A "How-To" Technique Using Helical Tomotherapy and Linear Accelerator-Based Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1244-1252.	0.8	313
330	Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy: In Regard to Song et Al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1281.	0.8	0
331	PROOF OF PRINCIPLE OF OCULAR SPARING IN DOGS WITH SINONASAL TUMORS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY. <i>Veterinary Radiology and Ultrasound</i> , 2010, 51, 561-570.	1.1	66
332	Brain Metastases. <i>Medical Radiology</i> , 2010, , 209-223.	0.0	0
333	A multigene predictor of outcome in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 49-57.	1.2	343
334	Current Treatment Strategies for Brain Metastasis and Complications From Therapeutic Techniques. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 398-407.	1.3	65
335	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. <i>Neuro-Oncology</i> , 2010, 12, 87-94.	1.2	47
336	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). <i>Neuro-Oncology</i> , 2010, 12, 855-861.	1.2	188
337	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. <i>Neuro-Oncology</i> , 2010, 12, 95-103.	1.2	258
338	Current Therapeutic Paradigms in Glioblastoma. <i>Reviews on Recent Clinical Trials</i> , 2010, 5, 14-27.	0.9	67
339	Gangliogliomas" what is the appropriate management strategy?. <i>Nature Reviews Neurology</i> , 2010, 6, 190-191.	10.0	4
340	Radiographic Pneumonitis Patterns and Low Pulmonary Toxicity After Helical Tomotherapy. <i>American Journal of Roentgenology</i> , 2010, 194, W459-W459.	2.8	5
341	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. <i>Radiotherapy and Oncology</i> , 2010, 95, 327-331.	0.6	171
342	Why avoid the hippocampus? A comprehensive review. <i>Radiotherapy and Oncology</i> , 2010, 97, 370-376.	0.6	323

#	ARTICLE	IF	CITATIONS
343	Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. <i>Journal of Clinical Oncology</i> , 2009, 27, 733-739.	15.4	108
344	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2171-2180.	1.9	15
345	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. <i>Neuro-Oncology</i> , 2009, 11, 167-175.	1.2	55
346	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 149-158.	1.9	32
347	EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antiplogenic Therapy. <i>Science Signaling</i> , 2009, 2, ra82.	5.1	287
348	On the Estimation of the Location of the Hippocampus in the Context of Hippocampal Avoidance Whole Brain Radiotherapy Treatment Planning. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 425-432.	1.9	12
349	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	133
350	A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1006-1011.	0.8	47
351	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 91, 183-189.	3.0	69
352	Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. <i>Journal of Neuro-Oncology</i> , 2009, 95, 247-257.	3.0	40
353	Prognostic indices for brain metastases – usefulness and challenges. <i>Radiation Oncology</i> , 2009, 4, 10.	2.7	93
354	Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 699-708.	0.8	95
355	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non-Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1069-1076.	0.8	162
356	Radiation Techniques in Neuro-Oncology. <i>Neurotherapeutics</i> , 2009, 6, 487-499.	4.7	13
357	A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1260-1269.	0.8	91
358	Commissioning and Quality Assurance of RapidArc Radiotherapy Delivery System: In Regard to Ling et al. (<i>Int J Radiat Oncol Biol Phys</i> 2008;72;575-581): Absence of Data Does Not Constitute Proof; The Proof is in Tasting the Pudding. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 4-6.	0.8	18
359	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. <i>Medical Radiology</i> , 2009, , 335-346.	0.0	0
360	Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2008, 89, 313-337.	3.0	33

#	ARTICLE	IF	CITATIONS
361	Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 227-233.	2.4	55
362	A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 175-179.	2.4	7
363	The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. <i>Radiation Oncology</i> , 2008, 3, 32.	2.7	44
364	In Reply to Drs. Nieder and Molls. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1619.	0.8	0
365	Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Non-“Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1597-1603.	0.8	22
366	Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 71-78.	0.8	86
367	A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 79-86.	0.8	92
368	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 64-70.	0.8	260
369	In Reply to Drs. Weltman and Brandt. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1292-1293.	0.8	0
370	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Brain Pathology</i> , 2008, 18, 360-369.	4.2	125
371	Radiation Oncology Advances: An Introduction. <i>Cancer Treatment and Research</i> , 2008, 139, 1-4.	0.0	5
372	A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 510-514.	0.8	925
373	Correlation of O ⁶ -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. <i>Journal of Clinical Oncology</i> , 2008, 26, 4189-4199.	15.4	732
374	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 441-447.	1.9	65
375	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2008, 10, 162-170.	1.2	369
376	Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2008, 10, 631-642.	1.2	29
377	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. <i>Neuro-Oncology</i> , 2008, 10, 752-758.	1.2	48
378	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 300-305.	1.3	95

#	ARTICLE	IF	CITATIONS
379	Combined Chemoradiotherapy Advances. <i>Cancer Treatment and Research</i> , 2008, , 277-301.	0.0	1
380	Stereotactic Body Radiation Therapy: Fractionated Radiation Therapy Perspective. , 2008, , 635-642.		0
381	Cost-Effectiveness and Quality of Life. , 2008, , 663-671.		0
382	Resection versus radiosurgery for patients with brain metastases. <i>Future Oncology</i> , 2007, 3, 95-102.	2.4	12
383	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 785-794.	2.6	23
384	Megavoltage Computed Tomography. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 617-623.	1.3	31
385	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. <i>Journal of Clinical Oncology</i> , 2007, 25, 1260-1266.	15.4	303
386	Motexafin gadolinium in the treatment of brain metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 351-359.	1.9	30
387	Advances in Radiation Therapy for Brain Tumors. <i>Neurologic Clinics</i> , 2007, 25, 1005-1033.	1.9	25
388	B1-07: Decreased neurocognitive progression with Motexafin Gadolinium (MGd) plus Whole Brain Radiation Therapy (WBRT) in non-small cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials. <i>Journal of Thoracic Oncology</i> , 2007, 2, S335-S336.	1.2	0
389	PD5-2-8: Predictors of survival for non-small-cell lung cancer patients with brain metastases treated with whole brain radiation therapy: pooled data from two randomized trials. <i>Journal of Thoracic Oncology</i> , 2007, 2, S478.	1.2	0
390	Therapeutic management of metastatic brain tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 70-78.	4.5	38
391	Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 187-195.	0.8	93
392	Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 852-857.	0.8	49
393	Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 971-977.	0.8	176
394	Breathing-Synchronized Delivery: A Potential Four-Dimensional Tomotherapy Treatment Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1572-1578.	0.8	25
395	Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 831-838.	0.8	39
396	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 589-597.	0.8	178

#	ARTICLE	IF	CITATIONS
397	Therapeutic advances for glioblastoma multiforme: Current status and future prospects. <i>Current Oncology Reports</i> , 2007, 9, 66-70.	4.1	49
398	Impact of molecular profiling on clinical trial design for glioblastoma. <i>Current Oncology Reports</i> , 2007, 9, 71-79.	4.1	9
399	Radiation for Brain Metastases. <i>Cancer Treatment and Research</i> , 2007, 136, 91-115.	0.0	1
400	Advances in the Treatment of Brain Metastases. <i>Translational Medicine Series</i> , 2007, , 207-230.	0.0	0
401	Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors. <i>Radiotherapy and Oncology</i> , 2006, 78, 313-321.	0.6	54
402	Whole-Brain Radiotherapy in the Management of Brain Metastasis. <i>Journal of Clinical Oncology</i> , 2006, 24, 1295-1304.	15.4	436
403	Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Journal of Clinical Oncology</i> , 2006, 24, 2707-2714.	15.4	681
404	Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 732-733.	1.2	6
405	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 99-111.	4.5	32
406	Integral radiation dose to normal structures with conformal external beam radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 962-967.	0.8	145
407	Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. (<i>Int J Radiat Oncol Biol Phys</i> 2005;62:1549-1558). <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1288-1289.	0.8	7
408	A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1422-1428.	0.8	92
409	Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 135-141.	0.8	110
410	In response to Dr. Peñagaricano. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1274-1275.	0.8	1
411	Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon- β for supratentorial glioblastoma: Results of RTOG 9710. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 818-824.	0.8	51
412	Tomotherapy and Other Innovative IMRT Delivery Systems. <i>Seminars in Radiation Oncology</i> , 2006, 16, 199-208.	2.3	71
413	Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. <i>Acta Oncologica</i> , 2006, 45, 890-896.	1.9	71
414	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study ¹ . <i>Neuro-Oncology</i> , 2006, 8, 189-193.	1.2	203

#	ARTICLE	IF	CITATIONS
415	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 465-479.	1.9	85
416	Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3651-3656.	15.4	151
417	Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. <i>Journal of Clinical Oncology</i> , 2006, 24, 5711-5715.	15.4	524
418	Models Support Prophylactic Cranial Irradiation. <i>Journal of Clinical Oncology</i> , 2006, 24, 3524-3526.	15.4	22
419	Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211. <i>Neuro-Oncology</i> , 2006, 8, 47-52.	1.2	53
420	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. <i>Neurosurgery</i> , 2005, 57, 1193-1200.	1.3	47
421	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 779-788.	0.8	255
422	Accelerated hypofractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 299-300.	0.8	3
423	Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 318-327.	0.8	45
424	In response to Drs. Vordermark and KÅ¶l. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 297.	0.8	0
425	In reply to Dr. Kondziolka et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 615-616.	0.8	2
426	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 37-46.	0.8	327
427	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 47-55.	0.8	163
428	Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment?. <i>Seminars in Oncology</i> , 2005, 32, 25-34.	2.3	8
429	Potential for Radiation Therapy Technology Innovations to Permit Dose Escalation for Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, 107-113.	2.7	13
430	Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1281-1287.	4.1	37
431	A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. <i>Cancer</i> , 2005, 104, 1968-1974.	4.1	45
432	Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. <i>Pediatric Blood and Cancer</i> , 2005, 45, 676-682.	1.6	18

#	ARTICLE	IF	CITATIONS
433	Current Strategies in Whole-brain Radiation Therapy for Brain Metastases. <i>Neurosurgery</i> , 2005, 57, S4-33.	1.3	40
434	Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397). <i>Journal of Clinical Oncology</i> , 2005, 23, 8870-8876.	15.4	178
435	Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3760-3767.	15.4	151
436	Radiation Therapy for Leptomeningeal Cancer. , 2005, 125, 147-158.		24
437	Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6647-6656.	15.4	61
438	Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?. <i>Neurological Research</i> , 2005, 27, 387-398.	1.4	59
439	Strategies for enhanced radiation delivery in patients with lung cancer. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 103-113.	5.1	3
440	Current Management of Brain Metastases, With a Focus on Systemic Options. <i>Journal of Clinical Oncology</i> , 2005, 23, 6207-6219.	15.4	339
441	Basic Concepts Underlying Radiation Therapy. , 2005, , 70-74.		0
442	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4282-4289.	15.4	80
443	Helical Tomotherapy as a Means of Delivering Accelerated Partial Breast Irradiation. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 639-646.	1.9	41
444	The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 303-307.	1.9	33
445	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 44-54.	1.2	70
446	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 157-165.	15.4	529
447	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 691-703.	2.8	18
448	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. <i>Neuro-Oncology</i> , 2004, 6, 96-103.	1.2	55
449	Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2004, 6, 33-37.	1.2	57
450	O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. <i>Neuro-Oncology</i> , 2004, 6, 28-32.	1.2	31

#	ARTICLE	IF	CITATIONS
451	Management of brain metastases. <i>Seminars in Oncology</i> , 2004, 31, 693-701.	2.3	100
452	Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy. <i>Clinical Lung Cancer</i> , 2004, 5, 303-306.	2.7	48
453	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1122-1126.	0.8	17
454	Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 204-213.	0.8	31
455	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma. <i>Cancer</i> , 2004, 100, 1712-1716.	4.1	49
456	Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1346-1352.	0.8	81
457	The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 927-931.	0.8	121
458	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1107-1115.	0.8	18
459	Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 853-860.	0.8	538
460	A challenge to traditional radiation oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1241-1256.	0.8	276
461	American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1026-1032.	0.8	195
462	The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1639-1644.	0.8	137
463	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. <i>Current Problems in Cancer</i> , 2004, 28, 7-40.	2.1	17
464	Radiosurgery for Single and Multiple Brain Metastases. , 2004, , 139-164.		5
465	A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. <i>Lung Cancer</i> , 2004, 44, 111-119.	2.0	6
466	Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. <i>Lancet</i> , The, 2004, 363, 1665-1672.	12.1	2,284
467	A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. <i>Investigational New Drugs</i> , 2003, 21, 429-433.	2.7	6
468	Combined modality treatment for central nervous system malignancies. <i>Seminars in Oncology</i> , 2003, 30, 11-22.	2.3	15

#	ARTICLE	IF	CITATIONS
469	Image guidance for precise conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 89-105.	0.8	447
470	Craniospinal treatment with the patient supine. Medical Dosimetry, 2003, 28, 35-38.	0.8	23
471	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. Seminars in Radiation Oncology, 2003, 13, 3-12.	2.3	20
472	E-53. Helical tomotherapy: An innovative technological radiation therapeutic approach for lung cancer. Lung Cancer, 2003, 41, S67-S68.	2.0	0
473	Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394. Journal of Clinical Oncology, 2003, 21, 1485-1491.	15.4	131
474	RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. Journal of Clinical Oncology, 2003, 21, 2364-2371.	15.4	101
475	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. Journal of Clinical Oncology, 2003, 21, 2529-2536.	15.4	441
476	Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2003, 21, 2305-2311.	15.4	151
477	Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery. Technology in Cancer Research and Treatment, 2003, 2, 79-85.	1.9	32
478	A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of the Children's Cancer Group-0952. Neuro-Oncology, 2003, 5, 8-13.	1.2	39
479	Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 70-78.	1.3	80
480	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 273-279.	1.3	13
481	Neurocognitive and Functional Assessment of Patients With Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 273-279.	1.3	71
482	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. Technology in Cancer Research and Treatment, 2002, 1, 311-316.	1.9	151
483	Fractionated Stereotactic Radiotherapy: A Short Review. Technology in Cancer Research and Treatment, 2002, 1, 153-172.	1.9	25
484	Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points. Journal of Clinical Oncology, 2002, 20, 3445-3453.	15.4	141
485	A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncology, 2002, 4, 109-114.	1.2	46
486	Neurocognitive sequelae of cancer treatment. Neurology, 2002, 59, 8-10.	1.1	39

#	ARTICLE	IF	CITATIONS
487	Trastuzumab for Breast Cancer–Related Carcinomatous Meningitis. <i>Clinical Breast Cancer</i> , 2002, 2, 316.	2.6	17
488	Three-dimensional conformal radiotherapy for lung cancer: Promises and pitfalls. <i>Current Oncology Reports</i> , 2002, 4, 347-353.	4.1	8
489	A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 519-526.	0.8	515
490	What is the appropriate primary end point for clinical trials for patients with brain metastases? In Response to Drs. Burri and Asher. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1394.	0.8	4
491	Optically guided intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2001, 61, 33-44.	0.6	45
492	Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases. <i>Journal of Clinical Oncology</i> , 2001, 19, 2074-2083.	15.4	126
493	Multiple daily fractionation radiotherapy schedules in lung cancer. <i>Current Oncology Reports</i> , 2001, 3, 179-184.	4.1	4
494	A new approach to dose escalation in non–small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 23-33.	0.8	241
495	Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1199-1206.	0.8	37
496	A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. <i>Cancer</i> , 2001, 91, 417-422.	4.1	89
497	Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy. <i>International Journal of Cancer</i> , 2001, 96, 320-325.	5.4	15
498	Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 426-434.	0.8	262
499	A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). <i>Journal of Neuro-Oncology</i> , 2000, 47, 145-152.	3.0	32
500	Radiotherapy for brain tumors. <i>Current Oncology Reports</i> , 2000, 2, 438-444.	4.1	11
501	Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 2, 48-52.	2.7	25
502	Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. <i>Journal of Clinical Oncology</i> , 1999, 17, 984-984.	15.4	70
503	Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2922-2922.	15.4	7
504	Radiosurgery for Brain Metastases. <i>Neurosurgery Clinics of North America</i> , 1999, 10, 337-350.	1.8	35

#	ARTICLE	IF	CITATIONS
505	Recurrent Malignant Gliomas Treated with Radiosurgery. <i>Journal of Radiosurgery</i> , 1999, 2, 119-125.	0.1	13
506	Comparison of Methods for Response Analysis of Central Nervous System Neoplasms. <i>Journal of Radiosurgery</i> , 1999, 2, 153-161.	0.1	3
507	Tomotherapy. <i>Seminars in Radiation Oncology</i> , 1999, 9, 108-117.	2.3	391
508	Development of a Unique Phantom to Assess the Geometric Accuracy of Magnetic Resonance Imaging for Stereotactic Localization. <i>Neurosurgery</i> , 1999, 45, 1423-1431.	1.3	69
509	Stereotactic Irradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 143-146.	1.3	25
510	The Status of Stereotactic Radiosurgery for Cerebral Metastases in 1998. <i>Journal of Radiosurgery</i> , 1998, 1, 17-30.	0.1	11
511	On "Stereotactic Radiosurgery for Patients with Single Brain Metastasis" (Cho et al., This Issue). <i>Journal of Radiosurgery</i> , 1998, 1, 87-88.	0.1	0
512	A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 445-454.	0.8	196
513	The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 469-475.	0.8	39
514	214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 123.	0.8	0
515	1021 Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: A rabbit model using visual evoked potentials, funduscopy and histology. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 226.	0.8	0
516	Thorotrast-associated Oropharyngeal Hemorrhage: Treatment by Means of Carotid Occlusion with Use of Flow Arrest and Fibered Coils. <i>Journal of Vascular and Interventional Radiology</i> , 1996, 7, 709-712.	0.5	4
517	Localized 2DJ-resolved H MR spectroscopy of human brain tumors in vivo. <i>Journal of Magnetic Resonance Imaging</i> , 1996, 6, 453-459.	3.6	88
518	Manpower issues and training program directions in radiation oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 970.	0.8	0
519	A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 27-35.	0.8	519
520	The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. <i>Journal of Neuro-Oncology</i> , 1996, 30, 1-6.	3.0	48
521	Linear accelerator configurations for radiosurgery. <i>Seminars in Radiation Oncology</i> , 1995, 5, 203-212.	2.3	17
522	The physical, biologic, and clinical basis of radiosurgery. <i>Current Problems in Cancer</i> , 1995, 19, 270-328.	2.1	32

#	ARTICLE	IF	CITATIONS
523	Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1995, 32, 931-941.	0.8	175
524	Glioblastoma multiforme: "who should receive stereotactic boost therapy?" International Journal of Radiation Oncology Biology Physics, 1994, 30, 746.	0.8	0
525	Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1994, 30, 164-165.	0.8	7
526	Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. International Journal of Radiation Oncology Biology Physics, 1994, 30, 541-549.	0.8	146
527	Current radiosurgery practice: results of an astro survey. International Journal of Radiation Oncology Biology Physics, 1994, 28, 523-526.	0.8	50
528	Consensus statement on stereotactic radiosurgery quality improvement. International Journal of Radiation Oncology Biology Physics, 1994, 28, 527-530.	0.8	26
529	Thoracic volume radiation sparing following endobronchial brachytherapy: A quantitative analysis. International Journal of Radiation Oncology Biology Physics, 1993, 25, 703-707.	0.8	22
530	Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. International Journal of Radiation Oncology Biology Physics, 1993, 25, 309-313.	0.8	54
531	Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. International Journal of Radiation Oncology Biology Physics, 1993, 27, 963-967.	0.8	78
532	Response to editorial by Drs. Lanciano and corn. International Journal of Radiation Oncology Biology Physics, 1993, 27, 991.	0.8	0
533	Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors*. International Journal of Radiation Oncology Biology Physics, 1993, 27, 1241-1244.	0.8	53
534	Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. Journal of Neuro-Oncology, 1993, 15, 57-66.	3.0	34
535	Cavernous sinus cranial neuropathies: is there a dose-response relationship following radiosurgery?. International Journal of Radiation Oncology Biology Physics, 1993, 27, 477-480.	0.8	25
536	A Retrospective Review of Nodal Treatment for Vulvar Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 38-42.	1.3	39
537	Meningeal hemangiopericytoma: defining the role for radiation therapy. Journal of Neuro-Oncology, 1992, 14, 277-87.	3.0	69
538	Endobronchial brachytherapy: Wither prescription point. International Journal of Radiation Oncology Biology Physics, 1992, 23, 251.	0.8	1
539	Treatment of Wilms's Tumour. Drugs, 1991, 42, 766-780.	11.1	17
540	A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. International Journal of Radiation Oncology Biology Physics, 1991, 21, 491-500.	0.8	46

#	ARTICLE	IF	CITATIONS
541	Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1053-1060.	0.8	59
542	Effect of Endobronchial Radiation Therapy on Malignant Bronchial Obstruction. Chest, 1990, 97, 662-665.	0.9	46
543	Monte Carlo and convolution dosimetry for stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1027-1035.	0.8	49
544	Endobronchial irradiation: Is HDR better?. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1629.	0.8	0
545	90Y β -B72.3 Against pancreatic cancer: Dosimetric and biological analysis. International Journal of Radiation Oncology Biology Physics, 1990, 19, 627-631.	0.8	10
546	Minimization of small bowel volume within treatment fields utilizing customized "abdominal boards". International Journal of Radiation Oncology Biology Physics, 1990, 19, 469-476.	0.8	99
547	Endobronchial irradiation for malignant airway obstruction. International Journal of Radiation Oncology Biology Physics, 1989, 17, 847-851.	0.8	59
548	Radiation induced thyroid neoplasms 1920 to 1987: A vanishing problem?. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1471-1475.	0.8	31
549	Optimizing the Radiotherapy Treatment Planning Process for Glioblastoma. Neuro-Oncology Practice, 0, , .	1.5	0
550	Rethinking Classification and Categorization of Resection Extent and its Impact on Patient Survival in Glioblastoma: Was Walter Dandy Ahead of His Time?. Neuro-Oncology, 0, , .	1.2	0